(Q35739130)

English

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY

scientific article published on 24 May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1 reference

based on heuristic

inferred from title

Robert S. Negrin

10

object named as

R Negrin

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

3

object named as

S Arai

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

author name string

S Naik

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

R Wong

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

J Brown

4

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

G Laport

5

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

R Lowsky

6

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

D Miklos

7

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

J Shizuru

8

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

K Blume

9

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

L Johnston

11

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

language of work or name

0 references

publication date

24 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

46

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

192-199

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

https://scigraph.springernature.com/pub.10.1038/bmt.2010.114

0 references

Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

12 July 2018

A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

12 July 2018

Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

12 July 2018

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

12 July 2018

The role of allogeneic transplantation in high-risk acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

12 July 2018

Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

12 July 2018

Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood a

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

12 July 2018

Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

12 July 2018

Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

12 July 2018

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

12 July 2018

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

12 July 2018

Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

Chemotherapy versus transplants for acute myelogenous leukemia in second remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4466222

25 September 2018

Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.114

21 January 2018

Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.114

21 January 2018

High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20498648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/20498648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic myeloablative transplantation for patients aged 50 years and over

1 reference

https://pubmed.ncbi.nlm.nih.gov/20498648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/20498648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20498648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Technique for human marrow grafting

1 reference

https://pubmed.ncbi.nlm.nih.gov/20498648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression

1 reference

https://pubmed.ncbi.nlm.nih.gov/20498648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group st

1 reference

https://pubmed.ncbi.nlm.nih.gov/20498648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20498648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20498648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regimen-related toxicity in patients undergoing bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20498648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BMT.2010.114

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35739130&oldid=1813452212"